These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Kirby M; Yu DM; O'Connor S; Gorrell MD Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719 [TBL] [Abstract][Full Text] [Related]
4. Selectivity among dipeptidyl peptidases of the S9b family. Bjelke JR; Kanstrup AB; Rasmussen HB Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(4):3-7. PubMed ID: 17543192 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Kim SJ; Nian C; Doudet DJ; McIntosh CH Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314 [TBL] [Abstract][Full Text] [Related]
6. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Pei Z Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568 [TBL] [Abstract][Full Text] [Related]
7. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Zhao G; Taunk PC; Magnin DR; Simpkins LM; Robl JA; Wang A; Robertson JG; Marcinkeviciene J; Sitkoff DF; Parker RA; Kirby MS; Hamann LG Bioorg Med Chem Lett; 2005 Sep; 15(18):3992-5. PubMed ID: 16046120 [TBL] [Abstract][Full Text] [Related]
8. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568 [TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement. Mest HJ Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820 [TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Idris I; Donnelly R Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591 [TBL] [Abstract][Full Text] [Related]
11. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Oefner C; Pierau S; Schulz H; Dale GE Acta Crystallogr D Biol Crystallogr; 2007 Sep; 63(Pt 9):975-81. PubMed ID: 17704566 [TBL] [Abstract][Full Text] [Related]
12. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582 [TBL] [Abstract][Full Text] [Related]
13. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340 [TBL] [Abstract][Full Text] [Related]
14. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Chen P; Caldwell CG; Mathvink RJ; Leiting B; Marsilio F; Patel RA; Wu JK; He H; Lyons KA; Thornberry NA; Weber AE Bioorg Med Chem Lett; 2007 Nov; 17(21):5853-7. PubMed ID: 17869513 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Fukushima H; Hiratate A; Takahashi M; Mikami A; Saito-Hori M; Munetomo E; Kitano K; Chonan S; Saito H; Suzuki A; Takaoka Y; Yamamoto K Bioorg Med Chem; 2008 Apr; 16(7):4093-106. PubMed ID: 18243000 [TBL] [Abstract][Full Text] [Related]
16. Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site. Sheehan SM; Mest HJ; Watson BM; Klimkowski VJ; Timm DE; Cauvin A; Parsons SH; Shi Q; Canada EJ; Wiley MR; Ruehter G; Evers B; Petersen S; Blaszczak LC; Pulley SR; Margolis BJ; Wishart GN; Renson B; Hankotius D; Mohr M; Zechel JC; Michael Kalbfleisch J; Dingess-Hammond EA; Boelke A; Weichert AG Bioorg Med Chem Lett; 2007 Mar; 17(6):1765-8. PubMed ID: 17239592 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. Corbett JW; Dirico K; Song W; Boscoe BP; Doran SD; Boyer D; Qiu X; Ammirati M; Vanvolkenburg MA; McPherson RK; Parker JC; Cox ED Bioorg Med Chem Lett; 2007 Dec; 17(24):6707-13. PubMed ID: 17977724 [TBL] [Abstract][Full Text] [Related]
18. 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV. Kaelin DE; Smenton AL; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE; Duffy JL Bioorg Med Chem Lett; 2007 Nov; 17(21):5806-11. PubMed ID: 17851076 [TBL] [Abstract][Full Text] [Related]
19. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. Kowalchick JE; Leiting B; Pryor KD; Marsilio F; Wu JK; He H; Lyons KA; Eiermann GJ; Petrov A; Scapin G; Patel RA; Thornberry NA; Weber AE; Kim D Bioorg Med Chem Lett; 2007 Nov; 17(21):5934-9. PubMed ID: 17827003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]